Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)
Line of business: BlueAlliance (Commercial) & BlueAlliance Care+ (Medicaid)
Measure Description
Percentage of episodes for Members 3 months of age and older with a diagnosis of acute bronchitis/bronchiolitis that did NOT result in the dispensing of antibiotics on or 3 days after the episode date.
Measure Definitions
- Intake Period: Captures eligible episodes of treatment for acute bronchitis/bronchiolitis between July 1 of the year prior to the measurement year to June 30 of the measurement year.
- Episode Date: The date of service in any outpatient setting with a diagnosis of acute bronchitis/bronchiolitis.
Notes
- Intake Period: Captures eligible episodes of treatment for acute bronchitis/bronchiolitis between July 1 of the year prior to the measurement year to June 30 of the measurement year.
- Episode Date: The date of service in any outpatient setting with a diagnosis of acute bronchitis/bronchiolitis.
Exclusions
- Visits that result in an inpatient stay.
- Members in hospice during the measurement year.
- Members who died during the measurement year.
Best Practices
- Realtime bedside education regarding use of antibiotic.
- Consistent messaging regarding use of antibiotics.
- Educate patients regarding difference between bacterial vs. viral.
- Self-care script pad for over-the-counter treatment for viral infections.
- Choosing Wisely campaign.
- Messaging in treatment rooms, website, and social media platforms.
- Ongoing provider education.
Antibiotic Medications for AAB
Description | Prescription | ||
Aminoglycosides | Amikacin Gentamicin | Streptomycin Tobramycin | |
Aminopenicillins | Amoxicillin | Ampicillin | |
Beta-lactamase inhibitors | Amoxicillin-clavulanate Ampicillin-sulbaclam | Piperacilin-tazobaclam | |
First-generation cephalosporins | Cefadroxil | Cefazolin | Cephalexin |
Fourth-generation cephalosporins | Cefepime | ||
Lincomycin derivatives | Clindamycin | Lincomycin | |
Macrolides | Azithromycin | Clarithromycin | Erythromycin |
Miscellaneous antibiotics | Aztreonam Chloramphenicol Dalfopristin-quinupristin | Daptomycin Linezolid Metronidazole | Vancomycin |
Natural penicillins | Penicillin G benzathine-procaine Penicillin G potassium | Penicillin G procaine Penicillin G sodium | Penicillin V potassium Penicillin G benzathine |
Penicillinase resistant penicillins | Dicloxacillin | Nafcillin | Oxacillin |
Quinolones | Ciprofloxacin Gemifloxacin | Levofloxacin Moxifloxacin | Ofloxacin |
Rifamycin derivatives | Rifampin | ||
Second-generation cephalosporin | Cefaclor Cefotetan | Cefoxitin Cefprozil | Cefuroxime |
Sulfonamides | Sulfadiazine | Sulfamethoxazole-trimethoprim | |
Tetracyclines | Doxycycline | Minocycline | Tetracycline |
Third-generation cephalosporins | Cefdinir Cefixime | Cefotaxime Cefpodoxime | Ceftazidime Ceftriaxone |
Urinary anti-infectives | Fosfomycin Nitrofurantoin | Nitrofurantoin macrocrystals-monohydrate | Trimethoprim |
Coding Disclaimer
The analysis of any medical coding question related to a measure is dependent on the measure’s technical specifications including the factual situations present related to the member, the practice, the professionals, and the medical services provided.
Questions
Should you have specific coding or other questions related to the measure, please send your questions to BlueAlliance@bcbsnd.com.
HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).
